ClinicalTrials.gg
Not yet recruitingNCT07038499Updated Jun 26, 2025

Prevalence and Determinants of Migraine Among Headache Patients

An observational study in Headache (Migraine), sponsored by Universiti Tunku Abdul Rahman. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Universiti Tunku Abdul Rahman · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
158
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Migraine Disorders with a site in China — 34 open to participants now, 40 under way, 10 of them phase 3. Migraine Disorders · China.

Planned enrollment
15th of 19
158 · median 330
Started
2025
with 12 others
Observational
19 of 80
9 open now
Primary completion
2025-10
later than 4 of 39 live
Registered
63rd of 80
by date

Among the 80 studies in Migraine Disorders with a site in China, this one is the 15th largest by planned enrollment of the 19 observational ones that give a count, is one of 13 that started in 2025, is one of 19 observational ones, reaches primary completion later than 4 of the 39 other live ones, and was the 63rd registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

34 of the 80 studies in Migraine Disorders with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Migraine Disorders with a site in China, or all of them as a file.
02

Study summary

Migraine is a prevalent and disabling neurological condition that often coexists with other health issues, such as hypertension and impaired physical, mental, and social functioning. Understanding the prevalence of migraine and its associations with these health domains can provide valuable insights into the broader impact of migraine on overall well-being. By focusing on patients at the Affiliated Hospital of Hebei University of Engineering in China, this study can identify specific health burdens within this population, inform integrated clinical management strategies, and support the development of targeted interventions to improve patient outcomes and quality of life.

Read the detailed description

Migraine is a common and disabling neurological disorder that poses a significant public health burden worldwide. In China, the estimated prevalence of migraine is approximately 9.3%, with higher rates reported among women and individuals of working age. Despite being one of the most prevalent types of primary headache disorders, migraine remains underdiagnosed and undertreated in many regions of China, partly due to limited awareness and access to specialized care. Concurrently, hypertension is highly prevalent in the Chinese adult population, with nearly one in four adults affected, making it a leading contributor to cardiovascular morbidity. Emerging evidence suggests a potential bidirectional relationship between migraine and hypertension, possibly linked through shared pathophysiological mechanisms such as endothelial dysfunction, autonomic dysregulation, and inflammatory pathways.

Moreover, migraine is often associated with detrimental effects on physical, mental, and social health, including impaired physical function, increased pain intensity, depression, anxiety, fatigue, sleep disturbances, and reduced ability to participate in social roles and activities. However, studies exploring these multidimensional impacts in Chinese clinical populations remain limited.

Therefore, this study aims to investigate the prevalence of migraine and its association with hypertension as well as physical, mental, and social health domains among headache patients at the Affiliated Hospital of Hebei University of Engineering, China.

03

Conditions studied

  • Headache (Migraine)

Keywords

  • Pain
  • Headache
  • Migraine
  • Disability
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients attending at the Affiliated Hospital of Hebei University of Engineering, China.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with headache according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3).

Exclusion criteria

Exclusion Criteria:

  • Patients with other major diseases or severe mental disorders;
  • History of endocrine, immune, or nervous system diseases or other severe somatic diseases.
05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
158 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Prevalence of migraine

    The overall number and proportion of people with migraine (according to the International Classification of Headache Disorders, 3rd edition (ICHD-3))

    Time frame: Day 1

Secondary outcomes

  1. Correlation with hypertension

    Hypertension will be assessed using self-reported hypertension status (Yes/ No)

    Time frame: Day 1

  2. Correlation with physical (physical function, pain intensity), mental (depression, anxiety, fatigue, sleep disturbance) and social (ability to participate in social roles and activities)

    Patient-Reported Outcomes Measurement Information System (PROMIS) measures domains including physical (physical function, pain intensity), mental (depression, anxiety, fatigue, sleep disturbance) and social (ability to participate in social roles and activities). The total score of each domain is converted to a standardized T score. High scores mean more of the domains being measured.

    Time frame: Day 1

  3. Correlation with migraine disability

    The MIDAS (Migraine Disability Assessment) is a validated questionnaire used to measure headache-related disability over the past three months. It consists of five questions, each addressing the number of days affected by migraines. Each answer is recorded as a number of days. The higher score indicating more severe migraine disability

    Time frame: Day 1

  4. Correlation with quality of life

    The Migraine-Specific Quality of Life Questionnaire (MSQ) is a validated tool used to assess the impact of migraine on a patient's quality of life. Raw scores are first calculated by summing item responses for each domain. Raw scores are then transformed into a 0-100 scale, where higher scores indicate better quality of life.

    Time frame: Day 1

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Oct 2025, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 26, 2025
StartEst.
Jun 23, 2025
Primary completionEst.
Oct 31, 2025
CompletionEst.
Oct 31, 2025
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07038499
Lead sponsor
Universiti Tunku Abdul Rahman
Responsible party
Foo Chai Nien (Assiociate Professor, Universiti Tunku Abdul Rahman) — Principal investigator
First posted
Jun 26, 2025
Start date
Jun 23, 2025 (estimated)
Primary completion
Oct 31, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Jun 26, 2025

Study contacts

Chai Nien Associate Professor, PhD
Contact
foocn@utar.edu.my
+60123167252
Chai Nien Associate Professor, PhD
Contact
foocn@utar.edu.my
Chai Nien Associate Professor, PhD
principal investigator · Universiti Tunku Abdul Rahman

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion